Trial Profile
A Phase 1‚ open-label‚ 3-period‚ fixed sequence study analysing drug interactions with Bictegravir/emtricitabine/tenofovir-alafenamide in combination with Rifapentine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2021
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Rifapentine
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 20 Apr 2021 New trial record
- 10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections